The JAK kinase family, consisting of the protein kinases JAK 1–3 and TYK2, are attractive targets for pharmacological intervention to treat inflammatory and autoimmune diseases, especially rheumatoid arthritis, as well as several myeloproliferative disorders19–22. Here, TYK2 is linked to autoimmune disease.